{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:53:38Z","timestamp":1792166018909,"version":"4.4.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.1001\/jamaoncol.2021.0006","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T12:31:34Z","timestamp":1614861094000},"page":"693","source":"Crossref","is-referenced-by-count":112,"title":["Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline\n                    <i>BRCA<\/i>\n                    Variants"],"prefix":"10.1001","volume":"7","author":[{"given":"Milind","family":"Javle","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Shacham-Shmueli","sequence":"additional","affiliation":[{"name":"Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Varadhachary","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Halpern","sequence":"additional","affiliation":[{"name":"Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fogelman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Boursi","sequence":"additional","affiliation":[{"name":"Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Uruba","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Margalit","sequence":"additional","affiliation":[{"name":"Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Golan","sequence":"additional","affiliation":[{"name":"Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi210001r1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation.","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi210001r2","first-page":"1417","article-title":"Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.","volume":"31","author":"Fogelman","year":"2011","journal-title":"Anticancer Res"},{"issue":"4","key":"coi210001r3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"coi210001r4","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"coi210001r5","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of patients with pancreatic cancer: initial results from the Know Your Tumor Initiative.","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi210001r6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"coi210001r7","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-13-1239","article-title":"Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.","volume":"20","author":"Kim","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi210001r8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000346034","article-title":"Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients.","volume":"80","author":"Kim","year":"2013","journal-title":"Pathobiology"},{"key":"coi210001r9","journal-title":"Eur J Cancer"},{"issue":"2","key":"coi210001r10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2307\/2531495","article-title":"A two-stage design for choosing among several experimental treatments and a control in clinical trials.","volume":"45","author":"Thall","year":"1989","journal-title":"Biometrics"},{"key":"coi210001r12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors.","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"coi210001r13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"coi210001r14","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1158\/1535-7163.MCT-19-0208","article-title":"ATM dysfunction in pancreatic adenocarcinoma and associated therapeutic implications.","volume":"18","author":"Armstrong","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"coi210001r15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.","volume":"13","author":"Kubota","year":"2014","journal-title":"Cell Cycle"},{"issue":"30","key":"coi210001r16","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the management of ovarian cancer: ASCO guideline.","volume":"38","author":"Tew","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7540","key":"coi210001r17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer.","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"4","key":"coi210001r18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"coi210001r19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx176","article-title":"Genomic rearrangement signatures and clinical outcomes in high-grade serous ovarian cancer.","volume":"110","author":"Hillman","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"coi210001r20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ccell.2018.12.010","article-title":"Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.","volume":"35","author":"Connor","year":"2019","journal-title":"Cancer Cell"},{"key":"coi210001r11","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Accessed January 25, 2021. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2776814\/jamaoncology_javle_2021_oi_210001_1621005002.69732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T11:10:13Z","timestamp":1621509013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2776814"}},"subtitle":["Findings From 2 Phase 2 Nonrandomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2021.0006","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}